Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications

Research output: Contribution to journalReviewResearchpeer-review

  1. Partial inhibition of mitochondrial-linked pyrimidine synthesis increases tumorigenic potential and lysosome accumulation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Plasma lactate responses during and after submaximal handgrip exercise are not diagnostically helpful in mitochondrial myopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mitochondrial dysfunction induced by variation in the non-coding genome - A proposed workflow to improve diagnostics

    Research output: Contribution to journalLetterResearchpeer-review

  4. Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Muscle contractility of leg muscles in patients with mitochondrial myopathies

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Comment on Delanaye et al: Future perspectives regarding kidney function estimates and dose adjustments

    Research output: Contribution to journalLetterResearchpeer-review

  2. SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

    Research output: Contribution to journalReviewResearchpeer-review

  3. Estimating Renal Function Following Lung Transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Baris Afsar
  • Mads Hornum
  • Rengin Elsurer Afsar
  • Lale A Ertuglu
  • Alberto Ortiz
  • Adrian Covic
  • Daniel H van Raalte
  • David Z I Cherney
  • Mehmet Kanbay
View graph of relations

Therapy for diabetic kidney disease (DKD) is undergoing a revolution with the realization that some glucose-lowering drugs have nephroprotective actions that may be intrinsic to the drugs and not dependent on the impact on diabetes control, as demonstrated with the sodium glucose co-transporter-2 (SGLT-2) inhibitors. Mitochondria are a critical factor required for the maintenance of kidney function, given its high energy demanding profile, with extensive use of adenosine triphosphate (ATP). Consequently, deficiency of the master regulator of mitochondrial biogenesis peroxisome proliferator-activated receptor gamma coactivator 1α predisposes to kidney disease. Perhaps as a result of key role of mitochondria in fundamental cellular functions, mitochondrial dysfunction may play a role in the pathogenesis of common conditions such as DKD. Finding pharmacological agents to influence this pathway could therefore lead to early implementation of therapy. Importantly, glucose-lowering drugs such as glucagon-like peptide-1 receptor activators and SGLT2 inhibitors have kidney and/or cardioprotective actions in patients with diabetes. Accumulating evidence from preclinical studies has suggested a protective effect of these drugs that is in part mediated by normalizing mitochondrial function. We now critically review this evidence and discuss studies needed to confirm mitochondrial protective benefits across a range of clinical studies.

Original languageEnglish
JournalMitochondrion
Volume58
Pages (from-to)72-82
Number of pages11
ISSN1567-7249
DOIs
Publication statusPublished - May 2021

Bibliographical note

Copyright © 2021. Published by Elsevier B.V.

ID: 69765132